The Covid-19 pandemic has created sudden changes in society and in the organisational landscape where working from home practices have been applied on a large scale to reduce the spread of the virus. The restrictions from governments and changing working environments have affected people's lifestyles. Furthermore, certain countries have also initiated formal lockdowns which has not been the case in Sweden where recommendations have been given to work from home. This research aims to find out how managers are adopting to and dealing with changing organisational practices that are impacted by different institutional pressures such as values, regulations and change. This study focuses on managers to find out how they have adjusted to working from home practices and managed challenges from it but also to understand their arguments and considerations about future work constellations. By this material we aspire to provide managers with information in terms of organising working practices when society is going back to normal which highlights risks and opportunities with working from home and future hybrid working arrangements.

Research questions: What effects can institutional pressures have on firms' sustainable activities? How can firms interact with their stakeholders to overcome the challenge of being sustainable and profitable?  Purpose: As sustainability is on the agenda for institutions worldwide, there is relevance in elevating the understanding of how institutional pressures impact firms' sustainable activities, and what mechanisms that firms can incorporate when developing CSR activities. Thus, we wish to contribute to the strategic benefits of stakeholder interaction to balance profitability and sustainability.  Method: Explorative, qualitative, case study. Conclusion: Institutional pressures have a significant impact on firms’ sustainable activities where the two main drivers are laws and regulations and the market demand. As a result, the main activities that these pressures bring forth include sustainability reporting, certifications, decreasing the carbon footprints, and the delivery of EPDs to the customers. Stakeholder interaction such as communication and collaboration can foster sustainable development and give a deeper understanding of mutually beneficial outcomes that enables firms to balance profitability and sustainability.

Les objectifs de la thèse sont de comprendre : 1) les mécanismes de diffusion, d’adoption et d’institutionnalisation des accréditations internationales, 2) les comportements stratégiques mobilisés à l’égard notamment du processus initial d’accréditation institutionnelle AACSB, 3) les réponses stratégiques et organisationnelles pour gérer les demandes institutionnelles conflictuelles provoquées par les injonctions des 21 standards AACSB (2003) et 4) les changements opérés en vue de l’alignement aux injonctions du processus initial prescrit et des 21 standards AACSB (2003). Dans une perspective néo-institutionnaliste, nous mobilisons un cadre d’analyse alliant les comportements stratégiques et le changement institutionnel. Pour répondre aux objectifs de la recherche, une étude de cas longitudinale rétrospective et en temps réel sur 15 ans d’une business school universitaire française est menée. Les résultats de la recherche permettent d’enrichir notamment le cadre d’analyse d’Oliver (1991) d’une sixième réponse stratégique et de trois tactiques dans le cas d’un processus initial d’accréditation institutionnelle AACSB. / This research aims to understand: 1) the mechanisms of diffusion, adoption and institutionalization of international accreditations, 2) the strategic behaviors adopted to respond to the initial AACSB accreditation process, 3) the strategic and organizational responses to the conflictual demands originated by the 21 AACSB 2003 standards and 4) the changes occurred in order to ensure the organizations’ alignment to the 21 AACSB 2003 standards and to the required process.Based on a neo-institutional perspective, we used two conceptual frameworks about strategic responses and institutional change. In order to comply with our objectives, we have conducted a 15-year longitudinal case study both retrospectively and in real time within the only French business school operating inside a university. The principal result of the research is the identification of a 6th new strategic response for Oliver’s (1991) framework as well as three tactics to be adopted in the initial AACSB accreditation process.

Made available in DSpace on 2010-04-20T20:51:05Z (GMT). No. of bitstreams: 3 166827.pdf.jpg: 21279 bytes, checksum: a3fc9d7da663db48cf918956841735bf (MD5) 166827.pdf: 1099445 bytes, checksum: a061e47acbd690633dfe449b6aa812b7 (MD5) 166827.pdf.txt: 337566 bytes, checksum: 85260a09c8500dc0e49b3b1e9f6eeae7 (MD5) Previous issue date: 2007-02-26T00:00:00Z / The objective of this work was to develop the concept of institutional strategy, applying it to the specific context of the pharmaceutical market competition by the time of the generic drugs regulation in Brazil. Institutional strategy implies a combined view of the technical and institutional facets of both the environment and the organizations, recognizing that agency condition and possibilities are socially constructed. It must be addressed while formulating or executing business strategy. The concept relies on well-known elements of institutional theory in organizational analysis, even though neglected by business strategy mainstream theories, anchored on neoclassic economic premises. Through content and documental analysis, with longitudinal perspective, the study identified institutional strategies and their influence on regulation accessed, as well as the consequent impact on economic performance of the various firms involved. In accordance to the theory framework developed, results found suggested that pharmaceutical companies performed institutional maneuvers, influencing changes in 'the rules of the game' or making use of them to obtain or sustain sources of economic rentals. Firms´ legitimacy as perceived by the other social actors limited these attempts. Several changes in regulation could be associated to the strategic maneuvers developed, and the impact of the new institutional arrangement on the economic performance of the firms observed. The study indicates that new elements ought to be included in traditional business strategy processes, specially a critical analysis of institutional pressures and the evaluation of strategic responses that might be perceived as legitimate by the other social actors involved. / Este trabalho procurou desenvolver o conceito de estratégia institucional, ilustrando sua aplicação no contexto específico da disputa de mercado pelas empresas farmacêuticas por ocasião da regulamentação dos medicamentos genéricos no Brasil. Estratégia institucional implica uma compreensão combinada das facetas técnica e institucional do ambiente e das organizações, e o reconhecimento da condição e das possibilidades de agência como socialmente construídas, sendo pertinente e relevante para aqueles que desejam formular e executar estratégias empresariais. O conceito apóia-se em elementos amplamente discutidos em Teoria Institucional em estudos organizacionais, porém negligenciados nas abordagens predominantes no campo da Estratégia Empresarial, ancoradas em pressupostos da economia neoclássica. Através de análise documental e análise de conteúdo, em perspectiva longitudinal, buscou-se caracterizar estratégias institucionais empregadas pelos laboratórios farmacêuticos, verificando-se a influência que tiveram sobre a regulamentação do setor, e o conseqüente impacto sobre o desempenho econômico das empresas. Os resultados encontrados, em linha com o referencial teórico desenvolvido, sugerem que as empresas empreenderam manobras institucionais, influenciando mudanças nas 'regras do jogo' ou fazendo uso delas para obter ou manter fontes de rendas econômicas, restringidas pela condição de legitimidade que lhes foi atribuída pelos outros atores. Diversas mudanças na regulamentação puderam ser associadas às manobras estratégicas, e o impacto do novo arranjo institucional sobre o desempenho das empresas pode ser observado. O estudo aponta a necessidade de incorporação de novos elementos aos processos e análises convencionais de estratégia de empresas, notadamente uma reflexão crítica sobre as pressões institucionais e a avaliação de respostas estratégicas que possam ser percebidas como legítimas pelos outros atores sociais envolvidos.

Submitted by ROSIANE SANT ANNA STUTZ (rosistutz@gmail.com) on 2017-12-27T19:10:18Z No. of bitstreams: 1 Dissertação_Rosi Stutz.pdf: 1924541 bytes, checksum: 466cc41030b03645511276ad7f864ddf (MD5) / Approved for entry into archive by Janete de Oliveira Feitosa (janete.feitosa@fgv.br) on 2018-01-02T13:02:49Z (GMT) No. of bitstreams: 1 Dissertação_Rosi Stutz.pdf: 1924541 bytes, checksum: 466cc41030b03645511276ad7f864ddf (MD5) / Made available in DSpace on 2018-01-09T17:04:22Z (GMT). No. of bitstreams: 1 Dissertação_Rosi Stutz.pdf: 1924541 bytes, checksum: 466cc41030b03645511276ad7f864ddf (MD5) Previous issue date: 2017-12-04 / Esta pesquisa objetivou investigar a manifestação do isomorfismo nos Códigos de Ética das empresas de capital aberto listadas na Bolsa de Valores do Brasil para verificar como a construção deste documento é influenciada por mecanismos institucionais que exercem pressão sobre estas empresas, inseridas no mesmo ambiente.Foi realizada uma pesquisa qualitativa, de caráter descritivo, conduzida por meio de análise do conteúdo dos Códigos de Ética de uma amostra que incluiu todos os setores econômicos utilizados pela Bolsa de Valores do Brasil. Para tratamento dos dados, o estudo utilizou categorias referentes às exigências da Legislação Brasileira, à legitimidade e às melhores práticas de um Programa de Compliance.A partir das categorias evidenciadas no conteúdo dos Códigos de Ética, esta pesquisa observou a ocorrência dos aspectos de isomorfismo coercitivo e de legitimidade em todos os Códigos, independente do setor econômico das empresas da amostra. Este estudo sugere que os Códigos analisados foram criados como uma resposta simbólica para atender as pressões de regulação e do ambiente institucionalizado onde as empresas estão inseridas.A presente pesquisa se limitou a analisar os conteúdos dos Códigos de Ética sob a luz da Teoria Institucional, concentrando-se no aspecto do isomorfismo e dos mecanismos institucionais que exercem pressão sobre as organizações inseridas em determinado campo organizacional, não abordando outros conceitos da Teoria nem realizando qualquer análise sobre a efetividade dos Códigos de Ética nas organizações selecionadas.O resultado deste estudo serve como um insumo relevante tanto para empresas que necessitam construir seu Código de Ética, quanto para as que necessitam aperfeiçoar o conteúdo de Códigos de Ética já existentes.As empresas podem construir seu Código de Ética como um guia efetivo de conduta para restringir comportamentos não éticos da organização e não apenas como um documento escrito para atender as exigências institucionais e regulatórias.Pelo nosso conhecimento, este é o primeiro estudo de conteúdo dos Códigos de Ética das empresas de capital aberto no Brasil, após a Legislação Brasileira Anticorrupção. / The purpose of this study is to investigate the occurrence of isomorphism in the Codes of Ethics of public companies listed on the Brazilian Stock Exchange to verify how the construction of this document is influenced by institutional mechanisms that put pressure on these companies, inserted in the same environment.A qualitative, descriptive research was carried out by analyzing the content of the Codes of Ethics of a sample that included all the economic sectors used by Brazilian Stock Exchange. For data treatment, the study used categories related to the requirements of the Brazilian Legislation, related to legitimacy and to the best practices of a Compliance Program.From the categories evidenced in the content of the Codes of Ethics, this study observed the occurrence of coercive isomorphism and legitimacy aspects in all Codes, regardless of the economic sector of the sample companies. This work suggests that the Codes analyzed were created as a symbolic response to address the pressure of regulation and the pressure of the institutionalized environment where the companies are inserted.This study was limited to analyze the content of the Codes of Ethics using the Institutional Theory, focusing on the aspect of the isomorphism and the institutional mechanisms that put pressure on the organizations inserted in a determined organizational field, not addressing other concepts of the Theory nor performing any analysis on the effectiveness of the Codes of Ethics in the selected organizations.The result of this study serves as a relevant input for both companies that need to build their Code of Ethics and those that need to improve the content of existing Codes of Ethics.Companies can build their Code of Ethics as an effective conduct guide to restrict employees’ unethical behavior and not just as a written document to meet institutional and regulatory requirements.To our knowledge, this is the first study of the Codes of Ethics content of public companies in Brazil, after the creation of the Brazilian Anti-Corruption Law.

Avec l’avènement de la micro-informatique dans les années 80, de l’internet dans les années 90 et de l’achèvement du séquençage du génome humain au tournant du 21e siècle, le nombre d’entreprises développant des technologies en santé a explosé. Par contre, la pratique en centre hospitalier et des interactions quotidiennes avec des professionnels de la santé œuvrant dans différents secteurs du système de santé québécois et d’autres provinces canadiennes rend compte d’une large différence entre le nombre de technologies qui apparaissent dans les conférences et blogs, et celles adoptées et utilisées sur le terrain. Mais tandis que l’évaluation des technologies et l’étude de la diffusion des innovations ont donné lieu à une littérature scientifique importante, peu d’études ont exploré jusqu’à présent l’émergence des entreprises de technologies innovantes en santé en prenant compte le point de vue de tous les acteurs impliqués. C’est donc ce manque de connaissances que notre étude désire combler, en se demandant comment une entreprise émergente et de technologie en santé peut se construire socialement en initiant certaines actions concurrentielles et pourquoi ces actions peuvent-elles différer selon le type d’entreprise, les demandes et les pressions des acteurs économiques et du système de santé. Les objectifs de recherche sont donc de définir comment les entreprises innovatrices en technologie de la santé s'établissent en utilisant l'effet de leurs actions concurrentielles tout en leur octroyant un sens, déterminer l'influence du type d'entreprise et des schèmes de construction sociale sur les actions concurrentielles, les activités de fabrication de sens et les réponses aux pressions des acteurs institutionnels, et enfin identifier quelles sont les stratégies utilisées par les entrepreneurs pour s'adresser à l'institution qu’est le système de santé. Afin de répondre aux interrogations soulevées par les observations sur le terrain, la présente recherche s’est organisée en trois volets successifs, explorant trois points de vue différents. Le premier est celui d’un observateur externe envers les startups en technologie de santé. Le deuxième volet est celui des acteurs gravitant autour de ces entreprises et le troisième est celui des entrepreneurs eux-mêmes. Le premier volet consiste en une étude de cas multiples utilisant la stratégie d’analyse de construction d’explication. L'étude s'est appuyée sur l'analyse des communiqués de presse (n = 664) et des articles des médias généraux (n = 627). L'échantillon comprend cinq entreprises canadiennes inscrites à la Bourse de Toronto sous la forme de quatre startups qui ont fait une offre d’achat initiale entre 2000 et 2003, et une entreprise bien établie. Parmi celles-ci, trois étaient dans le secteur de la santé, une dans le secteur du commerce électronique tandis que l‘entreprise bien établie était une entreprise de solutions d’infrastructures électroniques en santé. Globalement, au cours de l'émergence de l'entreprise, les actions marketing et symboliques, doublées du recours à des leaders d’opinion et des personnes de haute notoriété ont été nettement plus prononcées avec les startups de santé par rapport à l'entreprise qui n’était pas en santé. Au cours des premiers mois d’émergence, au fur et à mesure que les communications et signaux augmentaient, les startups en santé étaient les seules entreprises à utiliser la légitimité cognitive et pragmatique, s'appuyant ainsi sur la cognition plutôt que sur l'intérêt personnel ou les jugements moraux des acteurs. De plus, nous avons observé des différences dans l'utilisation des actions marketing et des actions symboliques et également dans le recours à des leaders d’opinion. Cela suggère une influence différentielle du modèle de construction sociale et du type d'entreprise sur le niveau et le mélange des actions du marché et des activités de sensibilisation entre les entreprises de santé et les entreprises de technologie non liées à la santé. Les deuxième et troisième volet consistent en deux séries d’entrevues semi-structurées, où une analyse thématique a été utilisée pour identifier et rapporter des thèmes tout en organisant et en décrivant minutieusement l'ensemble de données. Pour le deuxième volet, l'échantillon pour les entrevues semi-structurées comprend 10 médecins spécialistes, 4 professionnels de la santé impliqués dans l'acquisition des technologies de la santé, 3 membres des unités d'évaluation des technologies de la santé et 3 investisseurs en technologies de la santé. Nous avons déterminé que l'acquisition et la diffusion des technologies de santé sont de plus en plus réglementées et doivent répondre à des pressions croissantes d'un grand nombre d'acteurs qui voient inversement leur pouvoir d'agence se réduire. Nous avons également démontré que les pressions qui pousse vers l'institutionnalisation des pratiques, ainsi que le découplage des objectifs du système de santé et ceux des autres acteurs sont abordés par des stratégies "politiques"; le pouvoir des principaux influenceurs tels que les investisseurs et les spécialistes médicaux, ainsi que la méfiance à l'égard des actions de marketing sont abordés avec des stratégies “associatives”; les pressions découlant du besoin croissant de données fondées sur des données probantes sont traitées avec des stratégies “normatives”. Enfin, la faible fragmentation d'un système public de santé et l'hétérogénéité des processus d'acquisition locaux sont abordées avec des stratégies “d'identité”. Le troisième volet s’est concentré sur la manière dont les entrepreneurs saisissent les opportunités, créent leur organisation entrepreneuriale, et lui apportent de la légitimité, et a examiné les déclencheurs, contraintes et pressions impliquées dans ce processus. L'échantillon pour les entretiens a été constitué de 20 entrepreneurs et partenaires stratégiques impliqués dans le développement et la commercialisation des technologies de la santé. À chaque étape, nous avons identifié un processus institutionnel prédominant, qu'il s'agisse du découplage, de l'influence du champ organisationnel ou de la recherche de légitimation. Nous avons constaté que chaque étape de l'émergence de la start-up était déclenchée par des situations où l'entrepreneur faisait face à des barrières et contraintes sous la forme d'un désalignement des limites, de la mauvaise performance des technologies concurrentes, et de l'asymétrie des ressources. Nos résultats peuvent aider les professionnels de la santé, les décideurs et les évaluateurs à comprendre le processus d'adoption et de diffusion des technologies en santé et contribuer à l'élaboration de procédures d'acquisition grâce à des politiques ciblées et des processus révisés. Pour les investisseurs, notre étude leur permet d’identifier les obstacles qui rythment la vitesse à laquelle les nouvelles technologies font leur chemin dans la pratique clinique et le système de santé. Les résultats peuvent aussi fournir un cadre pour élaborer des données de référence pour évaluer les investissements actuels et futurs. Mieux connaître quelles sont les différences propres aux startups technologiques en santé en comparaison aux autres startups pourrait aider les entrepreneurs à prioriser les actions compétitives et à mieux cerner les intentions perçues et les besoins de santé réels lors de l’émergence sociale de l’entreprise. Pour le système de santé, les résultats peuvent servir à élaborer et enrichir des politiques et directives d’acquisition et d’évaluation qui vont améliorer l’accès à des technologies médicales qui sont sécuritaires, efficaces et de haute qualité. / With the advent of micro-computing in the 1980s, the Internet in the 1990s and the completion of the sequencing of the human genome at the turn of the 21st century, the number of companies developing health technologies has exploded. Nonetheless, hospital practice and day-to-day interactions with health professionals working in different sectors of the Quebec health system and other Canadian provinces reflect a large difference between the number of technologies appearing in conferences and blogs, and those adopted and used in the field. But while the evaluation of technologies and the study of the diffusion of innovations led to an important scientific literature, few studies have so far explored the emergence of innovative health technology companies taking into account the point of view of all the actors involved. It is this lack of knowledge that our study wishes to fill, by asking how an emerging health technology company can be socially constructed by initiating certain competitive actions and why these actions may differ according to the type of company, demands and pressures from economic and healthcare system actors. The research objectives are therefore to define how innovative health technology companies establish themselves by using the effect of their competitive actions while giving them meaning, determining the influence of the type of business and the patterns of social construction activities on competitive actions, sensemaking activities and responses to the pressures of institutional actors, and finally identify the strategies used by entrepreneurs to address the institution that is the health system. In order to answer the questions raised by field observations, this research was organized in three successive parts, exploring three different points of view. The first is that of an external observer to health technology start-ups. The second part is that of the actors around these companies and the third is that of the entrepreneurs themselves. The first part consists of a multiple case study using explanation-building analysis strategy. The study was based on the analysis of press releases (n = 664) and general media articles (n = 627). The sample includes five Canadian companies listed on the Toronto Stock Exchange in the form of four startups that made an initial bid from 2000 to 2003 and a well-established firm. Of these, three were in the health sector, one in the e-commerce sector, while the well-established company was a health electronic infrastructure solutions company. Overall, during the emergence of the company, marketing and symbolic actions, coupled with the use of opinion leaders and high-profile people, were significantly more pronounced with the health-based startups when compared to the firm who was not in the health sector. In the early months of emergence, as communications and signals increased, health-based startups were the only firms to use cognitive and pragmatic legitimacy, relying on cognition rather than personal interest or moral judgment of the actors. In addition, we observed differences in the use of marketing and symbolic actions and also in the use of opinion leaders. This suggests a differential influence of the social construction model and firm type on the level and mix of market actions and sensegiving activities between health and non-health technology companies. The second and third components consist of two sets of semi-structured interviews, where a thematic analysis was used to identify and report themes while organizing and describing the data set thoroughly. For the second part, the sample for semi-structured interviews includes 10 medical specialists, 4 health professionals involved in health technology acquisition, 3 health technology assessment units’ members, and 3 investors in health technologies. We have determined that the acquisition and diffusion of health technologies are increasingly regulated and must respond to increasing pressures from a large number of actors who, conversely, see their agency power diminish. We also found that the pressures to institutionalize practices, as well as the decoupling of the objectives of the health system from those of other actors, are addressed by “political” strategies; the power of key influencers such as investors and medical specialists, as well as mistrust of marketing actions are addressed with “associative” strategies; the pressures arising from the growing need for evidence-based evidence are addressed through “normative” strategies. Finally, the fragmentation of a public health system and the heterogeneity of local procurement processes are approached with “identity” strategies. The third part focuses on how entrepreneurs seize opportunities, create their entrepreneurial organization, and give it legitimacy, and examined the triggers, constraints and pressures involved in this process. The sample for the interviews consisted of 20 entrepreneurs and strategic partners involved in the development and commercialization of health technologies. At each stage, we identified a predominant institutional process, whether it be the decoupling, the influence of the organizational field or the search for legitimation. We found that each stage of the start-up was triggered by situations where the entrepreneur faced barriers and constraints in the form of a misalignment of boundaries, poor performance of competing technologies, and of resource asymmetry. Our findings can help healthcare professionals, decision-makers and evaluators understand the process of adoption and diffusion of health technologies and contribute to the development of procurement procedures through targeted policies and revised processes. For investors, our study allows them to identify the barriers that pace the speed at which new technologies are making their way into clinical practice and the health care system. The results can also provide a framework for developing baseline data to evaluate current and future investments. A better understanding of the differences in health technology startups compared to other startups could help entrepreneurs prioritize competitive actions and better understand perceived intentions and real health needs during the social emergence of the company. For the healthcare system, the results can be used to develop and enrich procurement and evaluation policies and guidelines that will improve access to safe, effective and high quality medical technologies.